Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091273 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00091273 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 9 participants.
The verdict
NCT00091273, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or primary peritoneal cancer.
Interventions
- PROCEDURE adjuvant therapy
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL tetanus toxoid helper peptide
- BIOLOGICAL ovarian cancer peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091273
The ClinicalTrials.gov registry entry for NCT00091273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which adjuvant therapy is the first listed.
NCT00091273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091273 about?
NCT00091273 is a clinical study titled "Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or primary peritoneal cancer.
What is the current status of trial NCT00091273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00091273?
The interventions under investigation include: adjuvant therapy (PROCEDURE), sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), tetanus toxoid helper peptide (BIOLOGICAL), ovarian cancer peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091273?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.